Skip to content
Glow Compound GLOW under ordinary light.

GLOW peptide: the reading list

The papers behind the plates, plus the FDA records that answer a different kind of question.

Somewhere to begin

For the skin question, the GHK skin-regeneration review is where I begin. For a concrete repair experiment, the rat Achilles-tendon paper is a better starting point than a broad claim about recovery. The topical GHK-combination hair trial is the paper behind the hair-count plate.

The full-length thymosin beta-4 safety trial deserves its own place rather than being folded into a claim about the TB-500 fragment. The 2025 BPC-157 review and 2026 Sports Medicine review provide perspective on the limits of human evidence.

The formulation convention in the list records composition; it has no clinical trial or study link. No entry describes a controlled trial of the complete GLOW blend. For the regulatory question, FDA’s withdrawn-nomination table and its 503A framework belong together; neither a cosmetic label nor an advisory-meeting entry settles that question alone.

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. ↗
  3. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21:976-983. ↗
  4. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95:323-333. ↗
  5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. ↗
  6. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. ↗
  7. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. ↗
  8. Research-label formulation convention for the GLOW blend (10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial), described as a supplier labeling convention rather than a clinically validated dose. Compositional note compiled from the constituent research record; the blend is not a single regulated product and has no controlled trial.
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. ↗
  10. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. ('Nominated but withdrawn' entries for BPC-157; 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; and 'GHK-Cu (for injectable routes of administration)', with FDA's stated safety concerns.) ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B framework and bulks-list nomination process.) ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157, KPV, TB-500 and MOTs-C as bulk drug substances being considered for inclusion on the 503A bulks list — a scheduled discussion, not a decision; GHK-Cu is not on this agenda.) ↗
  14. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated. (Basis for the cosmetic-versus-drug distinction underlying GHK-Cu's dual status: topical 'Copper Tripeptide-1' is regulated under cosmetics rules and not subject to FDA pre-market drug approval, separate from the injectable-drug compounding question.) ↗
  15. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:118-122. ↗
  16. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗